Galera Therapeutics’ Stock Dips on FDA’s Phase 3 Trial Directive
Galera Therapeutics, a leading biopharmaceutical company, recently disclosed receiving official meeting minutes from a Type A meeting with the Food and Drug Administration (FDA) held